Top-Rated StocksTop-RatedNASDAQ:XENE Xenon Pharmaceuticals (XENE) Stock Price, News & Analysis $33.63 -0.64 (-1.87%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$33.28 -0.36 (-1.06%) As of 08/7/2025 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Xenon Pharmaceuticals Stock (NASDAQ:XENE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Xenon Pharmaceuticals alerts:Sign Up Key Stats Today's Range$32.93▼$34.6350-Day Range$28.72▼$34.7052-Week Range$26.74▼$46.00Volume602,944 shsAverage Volume926,728 shsMarket Capitalization$2.58 billionP/E RatioN/ADividend YieldN/APrice Target$54.82Consensus RatingBuy Company Overview Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. Read More Xenon Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreXENE MarketRank™: Xenon Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat, and ranked 367th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingXenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageXenon Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Xenon Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($3.10) to ($3.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenon Pharmaceuticals is -10.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenon Pharmaceuticals is -10.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenon Pharmaceuticals has a P/B Ratio of 3.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Xenon Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.48% of the outstanding shares of Xenon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverXenon Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Xenon Pharmaceuticals has recently increased by 6,945.45%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXenon Pharmaceuticals does not currently pay a dividend.Dividend GrowthXenon Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.48% of the outstanding shares of Xenon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverXenon Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Xenon Pharmaceuticals has recently increased by 6,945.45%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.77 News SentimentXenon Pharmaceuticals has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Xenon Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest2 people have searched for XENE on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Xenon Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $91.00 in company stock.Percentage Held by InsidersOnly 5.52% of the stock of Xenon Pharmaceuticals is held by insiders.Percentage Held by Institutions95.45% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xenon Pharmaceuticals' insider trading history. Receive XENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address XENE Stock News HeadlinesXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $54.82 Consensus PT from BrokeragesAugust 7 at 3:07 AM | americanbankingnews.comXenon Pharmaceuticals Issues Equity Inducement Grants to New EmployeesAugust 6 at 3:16 AM | theglobeandmail.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant. | The Oxford Club (Ad)Xenon to Report Q2 2025 Financial Results on August 11, 2025August 4, 2025 | financialpost.comFXenon to Report Q2 2025 Financial Results on August 11, 2025August 4, 2025 | globenewswire.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Sees Large Growth in Short InterestAugust 3, 2025 | americanbankingnews.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | globenewswire.comSee More Headlines XENE Stock Analysis - Frequently Asked Questions How have XENE shares performed this year? Xenon Pharmaceuticals' stock was trading at $39.20 at the start of the year. Since then, XENE stock has decreased by 14.2% and is now trading at $33.63. How were Xenon Pharmaceuticals' earnings last quarter? Xenon Pharmaceuticals Inc. (NASDAQ:XENE) posted its earnings results on Monday, May, 12th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.90) by $0.07. The biopharmaceutical company had revenue of $7.50 million for the quarter, compared to the consensus estimate of $1.64 million. Read the conference call transcript. Who are Xenon Pharmaceuticals' major shareholders? Top institutional investors of Xenon Pharmaceuticals include Jennison Associates LLC (0.91%), Aberdeen Group plc (0.68%), Assenagon Asset Management S.A. (0.57%) and Bank of New York Mellon Corp (0.57%). Insiders that own company stock include Ian Mortimer, Dawn Svoronos, Gary Patou, James R Empfield, Sherrington Robin, Steven Gannon, Simon N Pimstone, Sherry Aulin and Christopher John Kenney. View institutional ownership trends. How do I buy shares of Xenon Pharmaceuticals? Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xenon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xenon Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Deckers Outdoor (DECK), Adobe (ADBE) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings5/12/2025Today8/07/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XENE CIK1582313 Webwww.xenon-pharma.com Phone(604) 484-3300Fax604-484-3450Employees210Year FoundedN/APrice Target and Rating Average Price Target for Xenon Pharmaceuticals$54.82 High Price Target$67.00 Low Price Target$47.00 Potential Upside/Downside+63.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($3.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$234.33 million Net MarginsN/A Pretax Margin-3,406.93% Return on Equity-32.44% Return on Assets-30.84% Debt Debt-to-Equity RatioN/A Current Ratio17.66 Quick Ratio17.66 Sales & Book Value Annual Sales$7.50 million Price / Sales344.08 Cash FlowN/A Price / Cash FlowN/A Book Value$9.90 per share Price / Book3.40Miscellaneous Outstanding Shares76,734,000Free Float72,498,000Market Cap$2.58 billion OptionableOptionable Beta1.16 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:XENE) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.